Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the…
Tag: Xeltis
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing
EINDHOVEN, The Netherlands – 14 August 2023, Xeltis a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels today announces the closing of an additional €12.5 million in funding from the European Innovation Council (EIC) Fund, set up by the European Commission. Today’s extension […]
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer of transformative implants that enable the natural creation of living […]
Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve
Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions EINDHOVEN, the Netherlands & ZURICH–(BUSINESS WIRE)–Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To […]
Xeltis Closes $52M for Replacement Heart Valve Programs
EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 /PRNewswire/ — Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed EUR45 million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation […]
